JP2011519375A5 - - Google Patents

Download PDF

Info

Publication number
JP2011519375A5
JP2011519375A5 JP2011507449A JP2011507449A JP2011519375A5 JP 2011519375 A5 JP2011519375 A5 JP 2011519375A5 JP 2011507449 A JP2011507449 A JP 2011507449A JP 2011507449 A JP2011507449 A JP 2011507449A JP 2011519375 A5 JP2011519375 A5 JP 2011519375A5
Authority
JP
Japan
Prior art keywords
composition
tumor
administered
days
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011507449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011519375A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/002645 external-priority patent/WO2009134396A2/en
Publication of JP2011519375A publication Critical patent/JP2011519375A/ja
Publication of JP2011519375A5 publication Critical patent/JP2011519375A5/ja
Pending legal-status Critical Current

Links

JP2011507449A 2008-04-30 2009-04-30 癌治療のためのコルチコトロピン放出因子の使用法 Pending JP2011519375A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4929208P 2008-04-30 2008-04-30
US61/049,292 2008-04-30
US9480608P 2008-09-05 2008-09-05
US61/094,806 2008-09-05
PCT/US2009/002645 WO2009134396A2 (en) 2008-04-30 2009-04-30 Methods of using corticotropin-releasing factor for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2011519375A JP2011519375A (ja) 2011-07-07
JP2011519375A5 true JP2011519375A5 (enExample) 2012-06-21

Family

ID=41119761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011507449A Pending JP2011519375A (ja) 2008-04-30 2009-04-30 癌治療のためのコルチコトロピン放出因子の使用法

Country Status (17)

Country Link
US (1) US20100113341A1 (enExample)
EP (1) EP2259793A2 (enExample)
JP (1) JP2011519375A (enExample)
KR (1) KR20110021820A (enExample)
CN (1) CN102036680A (enExample)
AU (1) AU2009241813A1 (enExample)
CA (1) CA2722426A1 (enExample)
CO (1) CO6300959A2 (enExample)
CR (1) CR11762A (enExample)
EC (1) ECSP10010631A (enExample)
IL (1) IL209005A0 (enExample)
MX (1) MX2010011882A (enExample)
NI (1) NI201000185A (enExample)
NZ (1) NZ588877A (enExample)
RU (1) RU2010148803A (enExample)
WO (1) WO2009134396A2 (enExample)
ZA (1) ZA201007729B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010057962A2 (en) * 2008-11-19 2010-05-27 Neutron Limited Crf conjugates with extended half-lives
KR20120124353A (ko) * 2009-06-24 2012-11-13 스티븐 에반스-프레케 암 치료를 위해 코르티코트로핀 방출인자를 사용하는 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2852054A (en) * 1956-11-23 1958-09-16 Motley Murat Brunson Container and closure therefor
US4312523A (en) * 1979-10-29 1982-01-26 Paco Packaging Incorporated Label for container having pharmaceutical product therein
US4415558A (en) 1981-06-08 1983-11-15 The Salk Institute For Biological Studies CRF And analogs
WO1984001378A1 (en) 1982-09-29 1984-04-12 Karl P Lederis Urotensin peptides
US4528189A (en) * 1983-02-03 1985-07-09 The Salk Institute For Biological Studies Urotensin peptides
US4489163A (en) * 1983-04-14 1984-12-18 The Salk Institute For Biological Studies rCRF and analogs
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするdna
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5229940A (en) * 1992-01-29 1993-07-20 Conoco Inc. Method of extracting three dimensional information from a grid of two dimensional seismic data
US5360352A (en) * 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5780431A (en) * 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
US6319900B1 (en) * 1999-09-21 2001-11-20 The Regents Of The University Of California Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs
CN1361180A (zh) * 2000-12-26 2002-07-31 上海博德基因开发有限公司 一种新的多肽——促肾上腺皮质激素释放因子8.8和编码这种多肽的多核苷酸
CN1382700A (zh) * 2001-04-26 2002-12-04 上海博德基因开发有限公司 一种多肽——促肾上腺皮质激素释放因子-12.87和编码这种多肽的多核苷酸
CA2358177A1 (en) * 2001-10-03 2003-04-03 Ted Ramsay Label for pharmaceutical prescriptions
US7919118B2 (en) * 2003-05-12 2011-04-05 Affymax, Inc. Spacer moiety for poly (ethylene glycol) modified peptide based compounds
WO2005117980A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
KR101235723B1 (ko) * 2004-07-08 2013-02-21 아임스코 리미티드 약제
JP2006036013A (ja) * 2004-07-27 2006-02-09 Yamaha Motor Co Ltd 自動二輪車
US7311205B2 (en) * 2005-01-25 2007-12-25 Target Brands, Inc. Pharmacy bottle system including label
US20100203048A1 (en) * 2008-04-30 2010-08-12 Stephen Evans-Freke Methods of using corticotropin-releasing factor for the use of the treatment of cancer

Similar Documents

Publication Publication Date Title
MY140826A (en) Substituted pyrazoline compounds, their preparation and use as medicaments.
EA201270570A1 (ru) Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
BR112012023021A2 (pt) compostos de indazol e seus usos
RU2015127794A (ru) Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в
WO2009152189A8 (en) Low dose topiramate/phentermine compostion and methods of use thereof
CL2014002935A1 (es) Metodo para tratar un paciente humano con esclerosis multiple con laquinimod, en una dosis diaria de alrededor de 1,2mg; un aforma de dosificacion unitaria oral de 1,2 mg de laquinimod y un portador
UA105644C2 (uk) Способи лікування легеневих порушень складами ліпосомального амікацину
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
CY1111588T1 (el) Υποκατεστημενα καρβοξαμιδια ως ανταγωνιστες μεταβολοτροπου υποδοχεα ομαδας ι
RU2012108439A (ru) Способы лечения опухолей головного мозга
WO2014052780A3 (en) Compositions and methods of use of an inappetance-controlling compound
MX2008011020A (es) Compuestos de receptor sigma.
RU2015112121A (ru) Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний
TW200738699A (en) 4-Substituted pyrazoline compounds, their preparation and use as medicaments
RU2016137926A (ru) Композиции грапипранта и способы их применения
JP2011519375A5 (enExample)
JP2015512948A5 (enExample)
TN2010000120A1 (en) Galenical formulations of organic compounds
TW200745042A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
RU2009145804A (ru) Аксомадол для лечения боли от артроза
WO2015004634A3 (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
PH12013501896A1 (en) Use of a sprayable composition comprising ambroxol